AbbVie Inc. (NYSE:ABBV) issued an update on its FY17 earnings guidance on Friday morning. The company provided earnings per share guidance of $5.53-5.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.54. AbbVie also updated its FY18 guidance to $6.37-6.57 EPS.
Several equities research analysts recently weighed in on the company. Vetr upgraded AbbVie from a hold rating to a buy rating and set a $76.28 target price for the company in a research note on Wednesday, July 26th. Deutsche Bank AG reiterated a hold rating and issued a $66.00 price objective (up previously from $65.00) on shares of AbbVie in a research note on Monday, July 17th. BidaskClub cut AbbVie from a strong-buy rating to a buy rating in a research note on Friday, July 28th. Jefferies Group LLC reiterated a buy rating and issued a $94.00 price objective (up previously from $92.00) on shares of AbbVie in a research note on Monday, July 17th. Finally, UBS AG reissued a neutral rating on shares of AbbVie in a report on Friday, October 13th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $93.68.
AbbVie Inc. (NYSE ABBV) opened at $95.43 on Monday. AbbVie Inc. has a 12-month low of $58.60 and a 12-month high of $98.26. The firm has a market capitalization of $152,347.33, a PE ratio of 17.97, a P/E/G ratio of 1.32 and a beta of 1.51. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.25 and a current ratio of 1.45.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.21 earnings per share. analysts predict that AbbVie Inc. will post 5.55 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.98%. AbbVie’s dividend payout ratio is currently 62.29%.
In other AbbVie news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert A. Michael sold 6,699 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the sale, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The disclosure for this sale can be found here. Insiders have sold 33,299 shares of company stock valued at $2,952,243 over the last 90 days. 0.23% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/13/abbvie-inc-abbv-releases-fy17-earnings-guidance.html.
Several hedge funds have recently bought and sold shares of ABBV. Ffcm LLC grew its stake in shares of AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after buying an additional 963 shares in the last quarter. Harvest Fund Management Co. Ltd grew its stake in shares of AbbVie by 1,172.6% in the second quarter. Harvest Fund Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $161,000 after buying an additional 2,052 shares in the last quarter. Acrospire Investment Management LLC grew its stake in shares of AbbVie by 223.9% in the second quarter. Acrospire Investment Management LLC now owns 2,604 shares of the company’s stock valued at $189,000 after buying an additional 1,800 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of AbbVie by 4.7% in the second quarter. Tower Research Capital LLC TRC now owns 2,629 shares of the company’s stock valued at $190,000 after buying an additional 119 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in AbbVie during the 2nd quarter valued at approximately $193,000. Institutional investors and hedge funds own 68.52% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.